Dr. Banerjee Describes Practice-Changing MM Data Presented at ASH 2024
By Melissa Badamo, Rahul Banerjee, MD, FACP - Last Updated: December 20, 2024Rahul Banerjee, MD, of the Fred Hutchinson Cancer Center, discussed notable studies in multiple myeloma (MM) presented at the 66th American Society of Hematology (ASH) Annual Meeting & Exposition. Key research includes the AQUILA study of daratumumab in high-risk smoldering MM, the CARTITUDE-4 trial of ciltacabtagene autoleucel versus standard of care in lenalidomide refractory MM, and more.
Advertisement
Advertisement
Related Posts
A QSP model of ISB 2001, a novel trispecific antibody, offers an effective pathway for designing phase 1 studies.
Efficacy and safety profile data were presented at the AACR Annual Meeting 2025.
CR1-02 was well-tolerated and led to stable disease in patients with relapsed or refractory AML.
The ASCO Association Board Chair has written letters to the new heads of the CMS, FDA, and NIH.
Sairah Ahmed, MD, tells about current management challenges and promising developments in treatment options.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.